Vertex Pharmaceuticals (VRTX) Stock Price Today—Real Time Charts and Quotes

Q: What's the stock price of Vertex Pharmaceuticals (VRTX) today?

Vertex Pharmaceuticals (VRTX) is currently trading at $434.67, with a 24h change of +0.38%. The 52-week trading range is $425.25–$463.24.

Q: What are the 52-week high and low prices for Vertex Pharmaceuticals (VRTX)?

VRTX has a 52-week high of $463.24 and a 52-week low of $425.25, with the current price at $434.67.

Q: What is the price-to-earnings (P/E) ratio of Vertex Pharmaceuticals (VRTX)? What does it indicate?

The current P/E ratio (TTM) of VRTX is 29.324130324800162, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals (VRTX) currently has a market cap of approximately $109.69B.

Q: What is the most recent quarterly earnings per share (EPS) for Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals (VRTX)'s diluted earnings per share (Diluted EPS) is 15.569909413154786. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Vertex Pharmaceuticals (VRTX) now?

As of now, VRTX is trading at $434.67, with a P/E ratio of 29.324130324800162 and a diluted EPS of 15.569909413154786. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Vertex Pharmaceuticals's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Vertex Pharmaceuticals (VRTX)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Vertex Pharmaceuticals (VRTX) stock?

You can buy Vertex Pharmaceuticals (VRTX) through Gate. Sign up for a Gate account and complete identity verification, then go to the Vertex Pharmaceuticals trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$434,67

+$1,66(+0,38 %)

*Data last updated: 2026-04-08 03:46 (UTC+8)

As of 2026-04-08 03:46, Vertex Pharmaceuticals (VRTX) is priced at $434,67, with a total market cap of $109,69B, a P/E ratio of 29,32, and a dividend yield of 0,00 %. Today, the stock price fluctuated between $425,25 and $440,63. The current price is 2,21 % above the day's low and 1,35 % below the day's high, with a trading volume of 981,93K. Over the past 52 weeks, VRTX has traded between $425,25 to $463,24, and the current price is -6,16 % away from the 52-week high.

VRTX Key Stats

Yesterday's Close$434,30

Market Cap$109,69B

Volume981,93K

P/E Ratio29,32

Dividend Yield (TTM)0,00 %

Diluted EPS (TTM)15,56

Net Income (FY)$3,95B

Revenue (FY)$12,07B

Earnings Date2026-05-04

EPS Estimate4,43

Revenue Estimate$3,06B

Shares Outstanding252,57M

Beta (1Y)0.367

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

SectorHealthcare

IndustryBiotechnology

CEOReshma Kewalramani

HeadquartersBoston,MA,US

Official Websitehttps://www.vrtx.com

Employees (FY)6,40K

Average Revenue (1Y)$1,88M

Net Income per Employee$617,68K

Erfahren Sie mehr über Vertex Pharmaceuticals (VRTX)

Gate Learn Articles

Eine detaillierte Erläuterung des Vertex-Protokolls

Dieser Artikel bietet ein detailliertes Verständnis von Vertex Protocol.

2024-02-27

Vertex-Protokoll: Arbitrums führendes Derivateprotokoll

Dieser Artikel bietet eine ausführliche Erläuterung der aktuellen Daten von Vertex, des Token-Einkommens, des Vergleichs mit anderen Projekten und zukünftiger Entwicklungspläne.

2024-03-03

Das erste Jahr zeigte, dass die Tokenomics nicht funktionierten.

Dieser Artikel liefert eine fundierte Analyse der entscheidenden Herausforderungen, denen sich die Token-Ökonomie im Jahr 2025 gegenübersieht. Regulatorische Rahmenbedingungen klassifizieren dezentrale Projekte zunehmend als traditionelle Wertpapiere oder Rohstoffe. Tokenrechte bleiben bei Fusionen und Übernahmen oft außen vor, während Protokolldividenden die regulatorischen Grenzen zur Wertpapierklassifizierung zunehmend erreichen. Diese Entwicklungen machen die grundlegende Kluft zwischen Token-Bewertung und rechtlicher Absicherung deutlich.

2026-01-22

Vertex Pharmaceuticals (VRTX) FAQ

What's the stock price of Vertex Pharmaceuticals (VRTX) today?

Vertex Pharmaceuticals (VRTX) is currently trading at $434,67, with a 24h change of +0,38 %. The 52-week trading range is $425,25–$463,24.

What are the 52-week high and low prices for Vertex Pharmaceuticals (VRTX)?

What is the price-to-earnings (P/E) ratio of Vertex Pharmaceuticals (VRTX)? What does it indicate?

What is the market cap of Vertex Pharmaceuticals (VRTX)?

What is the most recent quarterly earnings per share (EPS) for Vertex Pharmaceuticals (VRTX)?

Should you buy or sell Vertex Pharmaceuticals (VRTX) now?

What factors can affect the stock price of Vertex Pharmaceuticals (VRTX)?

How to buy Vertex Pharmaceuticals (VRTX) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.